CGTLive’s Weekly Rewind – May 27, 2022
Review top news and interview highlights from the week ending May 27, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Gene Therapy for Knee Cartilage Lesions Receives RMAT Designation
NeoCart was originally developed by the company Histogenics.
2. EtranaDez Accepted for Priority Review in Hemophilia B
A final analysis of the pivotal HOPE-B study was presented at ASGCT 2022.
3. Developing Safer Viral Vectors for Gene Therapy
The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.
4. Ami J. Shah, MD, on Reaching Normalized Hemoglobin With Gene Therapy in PKD
The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.
5. Gene Therapy for AADC Deficiency Receives Positive CHMP Opinion
The positive opinion was based on findings from studies conducted in Taiwan.
Enabling Wider Antigen Selection With Logic-Gated CAR T-Cell Therapy for Solid Tumors
November 25th 2023Maria Pia Morelli, MD, PhD, assistant professor, MD Anderson Cancer Center, discussed her work on the EVEREST-1 trial of logic-gated CAR T-cell therapy currently being evaluated in colorectal and pancreatic cancers.
